Nyxoah SA (NASDAQ:NYXH) stock is up during Tuesday’s premarket session. Year to date, the stock has plunged almost 70%.On Friday, the company priced its $95 million underwritten public offering. The offering aims to fund various initiatives, including commercialization efforts and research and development for its Genio system, a treatment for Obstructive Sleep Apnea.The offering is significant as it reflects Nyxoah’s commitment to expanding its market presence and enhancing its product offerings.Nyxoah Raises $95 Million Via EquityThe public offering consists of approximately 55.2 million ordinary shares priced at $1.72 each, with a 30-day option for underwriters to purchase additional shares.The proceeds are intended for expanding commercialization activities in the U.S. and advancing R&D for product enhancements and new technologies.Aims To Accelerate U.S. Commercial GrowthOn Thursday, the medical technology company focused on Obstructive Sleep Apnea commenced a leadership transition process to further accelerate its U.S. commercial traction.After seven years leading Nyxoah, Olivier Taelman, CEO, decided to exit.The Board has formally launched a search process to appoint a new U.S.-based CEO.Nyxoah reported a first-quarter loss of 43 cents, better than the consensus loss of 54 cents. Sales reached $7.46 million, beating the consensus of $7.13 million.The company expects fiscal 2026 sales of $42.16 million to $46.84 million, compared to the consensus of $37.2 million.NYXH Technical Outlook: Oversold Signals And Bearish TrendCurrently, Nyxoah’s stock is trading at $1.42, significantly below its moving averages, with the 20-day simple moving average (SMA) at $2.79, indicating a distance of about 48.3%.The stock’s relative strength index (RSI) is at 19.67, suggesting it is in oversold territory, which could indicate a potential reversal if buying interest increases.The bearish trend is further supported by the 20-day SMA being below the 50-day SMA, indicating a lack of upward momentum.Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $7.67. Recent analyst moves include: